ArticleInternational journal of biological sciences2023
Comprehensive pan-cancer analysis reveals NUSAP1 is a novel predictive biomarker for prognosis and immunotherapy response.
Article in International journal of biological sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 32 citations in OpenAlex.
- Review
- Identification of a biologically coherent three gene immune signature predictive of immunotherapy benefit in gastric adenocarcinoma.Discover oncology · 2026Article
- DNAJB6 as an immuno-oncogenic hub in liver hepatocellular carcinoma: multi-omic profiling reveals prognostic significance and therapeutic vulnerability.Journal of molecular histology · 2026Article
- NUSAP1 Drives Endometrial Carcinoma via IP3R Phosphorylation, Calcium Dyshomeostasis, and ER-Stress-Mediated Apoptosis.ACS omega · 2026Article
- Pan-cancer analysis of OSR2 with a focus on underlying mechanisms and therapeutic implications in lung adenocarcinoma.Frontiers in immunology · 2026Article
- FOXP1 transcriptionally activates NUSAP1 to induce M2 polarization of tumor-associated macrophages via glycolysis in hepatocellular carcinoma.Frontiers in genetics · 2026Article
- Multi-omics analysis and functional validation reveal the oncogenic role of TRIP13.Frontiers in immunology · 2026Article
- A case report of lymphoma presenting initially with tracheoesophageal fistula and literature review.Medicine · 2025Review
- Identification of prognostic biomarkers associated with T and melanoma cell subpopulations in melanoma through integrating machine learning and multiomics.Discover oncology · 2025Article
- Developing angiogenesis-related prognostic biomarkers and therapeutic strategies in bladder cancer using deep learning and machine learning.Scientific reports · 2025Article
- YY1 enhances HIF-1α stability in tumor-associated macrophages to suppress anti-tumor immunity of prostate cancer in mice.Nature communications · 2025Article
- The role and therapeutic value of NUSAP1 in human cancers.Journal of translational medicine · 2025Review
- The predictive value of peripheral blood monocytic myeloid-derived suppressor cells for survival and immunotherapy responses in tumor patients.BMC immunology · 2025Article
- In Silico Analysis Revealed a Role for NUSAP1 in Lung Adenocarcinoma through E2F1/hsa-let-7b-5p/lncRNA-TMPO-AS1.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Article
- Research progress on NUSAP1 and its role in digestive system neoplasms.Frontiers in oncology · 2025Review
- Single-cell sequencing elucidates the mechanism of NUSAP1 in glioma and its diagnostic and prognostic significance.Frontiers in immunology · 2025Article
- GLN2 as a key biomarker and therapeutic target: evidence from a comprehensive pan-cancer study using molecular, functional, and bioinformatic analyses.Discover oncology · 2024Article
- Article
- A comprehensive prognostic and immune infiltration analysis of UBA1 in pan-cancer: A computational analysis and in vitro experiments.Journal of cellular and molecular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nucleolar and spindle-associated protein 1 (NUSAP1) is a microtubule-associated protein that plays a crucial role in mitosis. Despite initial reports suggesting a potential involvement of NUSAP1 in tumor progression and malignant cell regulation, there has been no systematic analysis of its role in the tumor immune microenvironment, nor its predictive value for prognosis and immunotherapy response across different cancer types. In this study, we analyze NUSAP1 mRNA and protein expression levels in various human normal and tumor tissues, using data from TCGA, GTEx, CPTAC, HPA databases, and clinical samples. Our findings reveal that NUSAP1 is highly expressed in multiple tumor tissues across most cancer types and is primarily expressed in malignant and immune cells, according to single-cell sequencing data from the TISCH database. Prognostic analysis based on curated survival data from the TCGA database indicates that NUSAP1 expression levels can predict clinical outcomes for 26 cancer types. Furthermore, Gene Set Enrichment Analysis (GSEA) suggests that NUSAP1 promotes cell proliferation, tumor cell invasion, and regulation of anti-tumor response. Analysis of immune score, immune cell infiltration, and anti-cancer immunity cycle using ESTIMATE, TIMER, and TIP databases show that high NUSAP1 levels are associated with low CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.